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Summary
AIM: The study aim was to evaluate the cost effectiveness
of pembrolizumab monotherapy compared with
chemotherapy as a first-line treatment for previously un-
treated metastatic non-small cell lung cancer (NSCLC)
with programmed death ligand-1 (PD-L1) tumour propor-
tion score (TPS) ≥50%, from a Swiss payer perspective.
Cost effectiveness of pembrolizumab for this indication
has not previously been evaluated in Switzerland.
METHODS: We conducted an analysis using a partitioned
survival model with a cycle length of one week, base-
case time horizon of 20 years and discount rate of 3%
for cost and health outcomes. KEYNOTE-024 randomised
controlled trial data for pembrolizumab monotherapy com-
pared with chemotherapy was used as a basis for project-
ing time-on-treatment, progression-free survival and over-
all survival, over a 20-year period. For overall survival and
progression-free survival, we used Kaplan-Meier probabil-
ities for a brief initial period of the model, followed by para-
metric curves that had the best fit with subsequent trial
data. Quality-adjusted life years (QALYs) were calculated
based on the EuroQol 5-dimensional 3-level (EQ-5D-3L)
questionnaire administered to trial patients. Costs (in CHF,
year 2018) of drug acquisition/administration, adverse
events and disease management were included.
RESULTS: For the base-case, pembrolizumab monother-
apy resulted in mean incremental costs of CHF 77,060
(pembrolizumab CHF 223,324, chemotherapy CHF
146,264) and mean incremental QALYs of 1.34 (pem-
brolizumab 3.05, chemotherapy 1.71), leading to an incre-
mental cost-effectiveness ratio of CHF 57,402 per QALY
gained. Cost-effectiveness results were most sensitive to
overall survival and relatively insensitive to other parame-
ters varied. In probabilistic sensitivity analysis, the prob-
ability of cost effectiveness of pembrolizumab, with an
assumption of a willingness-to-pay threshold of CHF
100,000 per QALY gained, was 88%.
CONCLUSION: Pembrolizumab is likely to be cost effec-
tive for treating Swiss patients with previously untreated
metastatic NSCLC expressing PD-L1 TPS ≥50%. (This
economic evaluation was based on the KEYNOTE-024 tri-
al. The trial identifier is NCT02142738.)
Keywords: metastatic NSCLC, cost effectiveness, health
economics, PD-L1 positive, pembrolizumab, Switzerland
Introduction
Lung cancer accounts for approximately 3200 deaths in
Switzerland per year [1]. Eighty-five percent of lung can-
cers are of the non-small cell form (NSCLC) [2], and 46%
of NSCLC cases present with metastatic disease (stage 4)
upon initial diagnosis [3].
Immunotherapy drugs belonging to the programmed
death-1 (PD-1) inhibitor class, such as the humanised anti-
bodies pembrolizumab (Keytruda) and nivolumab, are re-
cent new treatments for NSCLC and other cancers. They
work through a novel mechanism of action involving
blocking the interaction between the programmed death
ligand-1 (PD-L1) protein on tumour cells and the PD-1
protein on immune (T) cells, so that the T cells remain acti-
vated and can kill the tumour cells [4]. Pembrolizumab has
received Swiss regulatory approval and is reimbursed in
Switzerland for patients with previously untreated metasta-
tic NSCLC with a PD-L1 tumour proportion score (TPS)
≥50% and no sensitising epidermal growth factor receptor
(EGFR) mutation or anaplastic lymphoma kinase (ALK)
translocation [5].
The KEYNOTE-024 trial in patients with previously un-
treated metastatic NSCLC demonstrated a significant im-
provement in overall and progression-free survival for pa-
tients receiving pembrolizumab compared with patients
receiving a platinum-based chemotherapy regimen [6, 7].
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A previous cost-utility analysis found pembrolizumab was
likely to be cost effective as first-line treatment of metasta-
tic NSCLC for US patients [8]. The aim of the present
study was to answer this question for Switzerland. We
used Swiss costs and long-term survival data, and
KEYNOTE-024 trial data to assess cost effectiveness of
first-line pembrolizumab monotherapy compared with
platinum-based chemotherapy in patients with previously
untreated metastatic NSCLC with PD-L1 TPS of ≥50% in
Switzerland.
Methods
A partitioned survival model, adapted from a previous
USA-based analysis [8], was used to project costs and out-
comes over 20 years for pembrolizumab and chemother-
apy. Incremental cost-effectiveness ratios (ICERs) in the
form of incremental cost per quality-adjusted life year
(QALY) gained and per life year gained were calculated.
The model was developed and implemented in Microsoft
Excel 2010.
The model was populated with effectiveness and resource-
use parameters primarily estimated directly from
KEYNOTE-024 trial data [7]. The KEYNOTE-024 trial
was used for the model as this is the only randomised con-
trolled trial that has assessed pembrolizumab monotherapy
only for NSCLC patients with PD-L1 ≥50% [6, 9]. For the
base-case analyses, we assumed the same treatment regi-
mens used in the trial, as alternative regimens and doses
might result in a different treatment effect, which is un-
known. Nevertheless, we consulted with Swiss clinical ex-
perts to establish a more realistic distribution of treatments
in Switzerland, which was considered in secondary analy-
ses. Furthermore, we used long-term Swiss cancer registry
data to implement a constant, equivalent mortality rate af-
ter 5 years for both treatment strategies. We did this as
evidence shows that if Swiss metastatic NSCLC patients
are alive 5 years after initiation of first-line treatment, the
survival rate thereafter is markedly different from the rate
before 5 years [10], so that the parametric probabilities
derived from trial data have less relevance after 5 years.
Effectiveness estimates, proportions of adverse events oc-
curring in trial patients and patients’ self-reported
EQ-5D-3L scores were derived from the KEYNOTE-024
trial, with a cut-off date of 9 May 2016. Costs (in CHF,
year 2018) of drug acquisition/administration, adverse
events and disease management were included. Unit cost
parameters were primarily obtained from the following
Swiss data sources: Spezialitätenliste (list of specialties)
for drug costs [5] and Swiss Diagnosis-Related Groups
(DRG) statistics for inpatient treatment costs due to ad-
verse events [11]. Some cost parameters were not available
from these databases; in this situation we undertook litera-
ture searches or contacted Swiss experts to determine their
values.
A time horizon of 20 years was used for the base-case
analysis, in order to capture most future costs and out-
comes associated with the treatment strategies. In a sce-
nario analysis we evaluated alternative time horizons of 5,
10 and 30 years to evaluate the sensitivity of model re-
sults to the time horizon chosen. An annual discount rate of
3% for costs and QALYs was used for the base-case analy-
sis, with alternative rates of 0% and 6% used in secondary
analyses. Analyses were conducted from the Swiss health-
care payer perspective. Contributions from Swiss patients,
insurers, the cantons and government are reflected in this
perspective.
Ethics approval of research
No specific ethical approval was obtained for this study,
as the present economic model did not involve recruitment
of human or animal subjects or collection of research sam-
ples.
Model structure and population
A partitioned survival model consisting of three health
states (progression-free disease, progressive disease and
death) was used to evaluate costs and outcomes for the two
treatment strategies (fig. 1). The population in the model
is based on KEYNOTE-024 participants who were adult
patients (mean age of 64 years) with metastatic stage 4
NSCLC expressing PD-L1 TPS ≥50% and baseline ECOG
(Eastern Cooperative Oncology Group) performance status
of 0 or 1, without EGFR-activating mutations or ALK
translocations, and who had not previously received sys-
temic chemotherapy for NSCLC [7]. We also conducted
a secondary analysis of a “test and treat” strategy, where
we evaluated the entire population of metastatic NSCLC
patients, with first-line pembrolizumab treatment only ad-
ministered to the proportion of metastatic NSCLC patients
with PD-L1 TPS ≥50% determined by a PD-L1 test; this
proportion in the KEYNOTE-024 trial was 30% [7].
Intervention and comparator
In KEYNOTE-024, patients in the pembrolizumab arm
received a 200 mg intravenous dose of pembrolizumab
once every 3 weeks for up to 2 years (35 cycles) [7],
which is consistent with pembrolizumab marketing autho-
risation in Switzerland [12]. Chemotherapy patients re-
ceived platinum-based chemotherapy every 3 weeks for
four to six cycles (four cycles is usually a valid treatment
option although some patients may receive one or two
additional cycles if they respond well) [13]. Forty-four
percent of chemotherapy patients received pemetrexed +
carboplatin, 24% received pemetrexed + cisplatin, 21% re-
ceived platinum + gemcitabine and 11% received pacli-
taxel + carboplatin [7]. This distribution of patients across
chemotherapy regimens was used for the base-case analy-
sis. Chemotherapy patients on a regimen not containing
gemcitabine were eligible to receive optional pemetrexed
maintenance therapy as part of their first-line treatment af-
ter completing four to six treatment cycles of their main
Figure 1: Model states and transitions.
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chemotherapy regimen if they had non-squamous disease
and were still progression free. We also undertook one sec-
ondary analysis where we reset the proportion of patients
receiving paclitaxel and carboplatin to 0% and redistrib-
uted them proportionally among the other chemotherapy
options, as we were advised by a Swiss clinical expert that
this is a rarely used chemotherapy regimen for NSCLC in
Switzerland.
Generally, treatment was continued for the specified num-
ber of cycles, or until documented disease progression, pa-
tient withdrawal, investigator decision or intolerable toxi-
city. The exception to this was that some pembrolizumab
patients continued to receive the drug after disease pro-
gression if they had clinically stable disease, had not ex-
ceeded the maximum treatment duration of 2 years and
were considered by the investigator to be still deriving
clinical benefit from pembrolizumab [7]. Documented dis-
ease progression was established by the investigating team
according to RECIST (Response Evaluation Criteria in
Solid Tumors) version 1.1 [7]. Chemotherapy patients
were eligible to switch to receive pembrolizumab follow-
ing a 30-day interval after their final chemotherapy treat-
ment, if they had documented disease progression, an
ECOG score of 0 and 1 and did not stop chemotherapy for
any reason other than their disease having become progres-
sive.
Survival analysis
Model effectiveness parameters were based on
KEYNOTE-024 data on time-on-treatment, progression-
free survival and overall survival (table 1) [8]. Parametric
models were fitted to the Kaplan-Meier (KM) trial data
for time-on-treatment, progression-free survival and over-
all survival as a basis for extrapolating effectiveness esti-
mates from the short-term trial period (median follow-up
of 11.3 months), to a 20 year period [8]. The parametric
models that were used are exactly the same models as
those used for the US analysis [8], and UK National In-
stitute for Health Care and Excellence (NICE) Decision
Support Unit guidelines were followed in fitting and se-
lection of the models [15]. The AIC (Akaike information
criterion) and BIC (Bayesian information criterion) statis-
tical tests combined with visual inspection of closeness of
parametric curves to Kaplan-Meier plots were used to se-
lect each base-case parametric model from the options: ex-
ponential, Weibull, Gompertz, log-logistic, log normal and
generalised gamma (see supplementary table S4 in appen-
dix 1). The clinical plausibility of the models was then
analysed by health economists and clinicians before deter-
mining final models used [8].
For time-on-treatment, the Weibull distribution was used
for pembrolizumab and generalised gamma distribution
was used for chemotherapy [8]. For progression-free sur-
vival, the Kaplan-Meier probabilities drawn from
KEYNOTE-024 data up to week 9 and Weibull distrib-
Table 1: Key model parameters.
Modelled strategy Overall survival Progression-free survival Time-on-treatment (first-line)
Pembrolizumab KM probabilities up to 32 weeks, exponential distribution from
32 weeks to year 5 (intercept = 5.323), NICER data from years
5 to 20*.
KM probabilities up to week 9,
Weibull distribution from week 9 to
year 20 (intercept = 4.772, ln(scale)
= 0.385)
Weibull distribution (intercept = 4.348,
ln(scale) = 0.57) (with cap after 2 years)
Chemotherapy KM probabilities up to 38 weeks, exponential distribution from
38 weeks to year 5 (intercept = 4.788), NICER data from years
5 to 20.
KM probabilities up to week 9, ex-
ponential distribution from week 9 to
year 20 (intercept = 3.262)
Generalised gamma distribution (mu =
3.217, sigma = −0.171, Q = 1.861)
Time-to-death categories Sample size Mean EQ-5D-3L score (95% confidence interval)
>360 days 54 0.79 (0.75–0.83)
181–360 days 26 0.70 (0.66–0.74)
30–180 days 68 0.61 (0.57–0.65)
<30 days 21 0.52 (0.40–0.63)
Costs† Cost (CHF) Source
Pembrolizumab drug cost (per 200 mg dose) 5218 Spezialitätenliste [5]
Average chemotherapy cost (per dose) 2834 Spezialitätenliste [5]
Pemetrexed maintenance cost (per dose) 3693 Spezialitätenliste [5]
Pembrolizumab/chemotherapy administration cost (first hour) 399 Matter-Walstra et al [14]
Pembrolizumab /chemotherapy administration cost (other hours) 52 Matter-Walstra et al [14]
PF disease management for pembrolizumab arm (weekly) 285 Huang [8], Matter-Walstra [14]
PF disease management for chemotherapy arm (weekly) 427 Huang [8], Matter-Walstra [14]
Progressive disease management (weekly) 661 Matter-Walstra et al [14]
PEM post-discontinuation therapy cost 12,626 KN-024, Spezialitätenliste [5]
Chemotherapy post-discontinuation therapy cost 28,232 KN-024, Spezialitätenliste [5]
Terminal care during last 30 days of life 22,816 DRG code A97, Luzerner Kantonspital
Adverse event Pembrolizumab Chemotherapy % hospitalised (esti-
mation)
Hospitalisation cost per
event (CHF)
Source (DRG code)
[11]
Anaemia 4.5 23.3 50 5929 E71B
Neutropenia 0.0 18.0 50 5929 E71B
Pneumonia 1.9 7.3 100 8466 E77F
Thrombocytopenia 0.0 12.0 30 5929 E71B
Pneumonitis 2.6 0.7 100 8466 E77F
DRG = diagnosis-related group; KM = Kaplan-Meier; NICER = National Institute for Cancer Epidemiology and Registration; PF = progression free; * We used a constant mortality
rate for overall survival from years 5 to 20, based on NICER data from 2000 to 2016, which recorded 46 deaths out of 124 living patients in Switzerland between 5 to 10 years
after diagnosis with stage 4 NSCLC [10]. † Where relevant, adjusted by inflation to 2018 values
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ution thereafter, were used for pembrolizumab; Kaplan-
Meier from KEYNOTE-024 data up to week 9 and expo-
nential distribution thereafter were used for chemotherapy
[8]. A week 9 cut-off was used because of a protocol-dri-
ven drop in measured progression-free survival at week 9
as the first tumour assessment was made at week 9 [8]. It is
not advisable to use the full Kaplan-Meier curve (depicted
in fig. 2 for time-on-treatment and fig. 3 for progression-
free survival) prior to utilising parametric extrapolation be-
yond the trial as the KM patient data become sparse and
estimates unstable as one nears the tail of the curve.
In order to model overall survival, a two-phase piecewise
approach was used, as this approach resulted in closer fit
with the trial data than the use of a parametric curve for
the entire model period which appeared inadequate upon
visual inspection unlike for progression-free survival af-
ter week 9 and time-on-treatment after week 0 [8]. There-
fore, Kaplan-Meier probabilities were used up to 32 weeks
for pembrolizumab and up to 38 weeks for chemotherapy
(the cut-offs were determined using the Chow test), and ex-
ponential distributions for both arms were used from then
up to year 5 [8]. A constant mortality rate of 0.0017 per
week per person derived from Swiss National Institute for
Cancer Epidemiology and Registration (NICER) data from
2000 to 2016 was applied to both arms from years 5 to
20 in the model for the base-case analysis (in a secondary
analysis, the exponential distributions were used for this
interval instead) [10]. The NICER-derived mortality rate
was calculated on the basis of a recorded 46 deaths out of
124 living patients in Switzerland between 5 to 10 years
after diagnosis of stage 4 NSCLC.
In a further secondary analysis, an adjustment to negate
costs and effects of a treatment switch to pembrolizumab
was made to overall survival in the chemotherapy arm us-
ing the simplified two-stage adjustment method of Latimer
et al. [16]. This was done to represent the hypothetical
scenario that the 66 patients in this arm who switched to
pembrolizumab during the trial did not switch. The ad-
justment for treatment switching was undertaken only as
a secondary analysis, in order that the base-case be more
reflective of Swiss clinical practice, in which second-line
pembrolizumab is recommended for metastatic NSCLC
patients treated with first-line chemotherapy.
Utility inputs
The EQ-5D-3L was administered to patients at treatment
cycles 1, 2, 3, 6, 9, 12 and subsequently at every third cycle
if the patient was still on study treatment. The EQ-5D-3L
was also administered to patients at the treatment discon-
tinuation visit and 30 days after the visit [8]. EQ-5D-3L
responses were converted to utility scores using the Eu-
ropean Union algorithm recommended for cancer patients
in Switzerland [17]. For the base-case analysis, EQ-5D-3L
scores were assigned to patients in each cycle of the model
according to the number of days they were projected to
be from dying as determined by the overall survival curve
(table 1) [8]. For this, pooled EQ-5D-3L scores for the fol-
lowing categories were used: >360, 180–360, 30–179 and
<30 days from death [8]. EQ-5D-3L scores were converted
to undiscounted QALYs in each model cycle by multiply-
ing the proportion of patients in each time-to-death group
for each 1-week cycle of the model, by the EQ-5D-3L
score assigned to that group and also by 7/365 (days). In a
secondary analysis, EQ-5D-3L scores were assigned to pa-
tients for each model cycle based on the disease state they
were in (progression-free, progressive disease or death).
All EQ-5D-3L assessments described in this section were
performed for the pooled sample of patients (across both
treatment arms, based on lack of statistical differences in
EQ-5D-3L scores between trial arms).
Resource utilisation and cost inputs
We considered costs related to drug acquisition and admin-
istration, disease management, post-discontinuation drugs,
adverse events management and terminal care. All costs
were updated to 2018 values using data on annual inflation
rates in Switzerland [18, 19].
Figure 2: Modelled time on first-line treatment.
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Drug acquisition and administration costs
Unit costs of drugs were taken from the Swiss Federal
Office of Public Health (SFOPH) Spezialitätenliste public
prices (table 1) [5]. Pembrolizumab is available for pur-
chase as a 100-mg vial costing CHF 2609 [5]. For the
chemotherapy arm, the dosage of chemotherapy drugs re-
ceived was determined by the body surface area (BSA) de-
rived for the model from the mean baseline BSA of Euro-
pean KEYNOTE-024 participants of 1.83 m2 [20]. From
this, we estimated the average cost of chemotherapy to be
CHF 2834 per dose (which was the average cost of the dif-
ferent chemotherapy regimens used weighted by the pro-
portions of chemotherapy patients who received each reg-
imen) and pemetrexed maintenance to be CHF 3693 per
dose (further details are provided in supplementary table
S1, appendix 1). Chemotherapy patients received option-
al pemetrexed maintenance after completing four to six
treatment cycles of their main chemotherapy regimen un-
til disease progression or unacceptable adverse events [6],
and analysis of the observed trial data showed that all
chemotherapy patients had discontinued pemetrexed main-
tenance after 72 weeks (fig. 2). Figure 2 also shows consis-
tency of observed time-on-treatment data from the trial to
the curves used in the modelling.
The cost of the first hour of drug administration for intra-
venous infusions was taken from an external study (CHF
399 after inflation adjustment) estimating this cost for
NSCLC in Switzerland (table 1); we varied this cost from
CHF 271 to CHF 588 in the one-way sensitivity analyses
(table S4, appendix 1) [14]. The cost of each subsequent
hour of drug administration after the first hour was as-
sumed to be CHF 52, which is 13% of the cost of the first
hour as was the case for the USA analysis; we varied this
cost from CHF 35 to CHF 77 in the one-way sensitivity
analyses [8].
First-line treatment duration in the model was based on
the estimated time-on-treatment curves. Furthermore, a cap
on treatment duration was manually implemented to the
time-on-treatment curve for pembrolizumab at 35 cycles (2
years) [5].
Unit costs of premedications for chemotherapy patients
were based on Spezialitätenliste public prices [5]. The
combinations and dose of the premedications were based
on the US model [8], and were confirmed by a Swiss on-
cologist to be relevant for Switzerland. This led to an es-
timated premedication cost for cisplatin of CHF 116.26
and carboplatin of CHF 19.81 per cycle. In the secondary
analysis of a “test and treat” strategy (described above in
the section “Model structure and population”), the PD-L1
test was an additional cost item included and its unit cost
was obtained from a study by Matter-Walstra et al. [14].
Disease management costs
Progressive disease management costs were obtained from
a study by Matter-Walstra et al., who estimated the cost
of providing best supportive care to patients with progres-
sive disease using data from the cantonal hospital Lucerne
(table 1) [14]. We were not aware of any published es-
timates of progression-free disease management costs in
Switzerland. Therefore, we made a proportional adjust-
ment to the cost of progressive disease management esti-
mated by Matter-Walstra et al. in order to estimate the cost
of managing progression-free disease in Switzerland [14].
The adjustment made for the base-case analysis was based
on the analysis from the USA, in which it was estimat-
ed that mean weekly progression-free disease management
costs represented 43.1% of mean weekly progressive dis-
ease management costs for patients in the pembrolizumab
group and 64.7% for patients in the chemotherapy group
[8]. In a secondary analysis, we instead assumed progres-
sion-free disease management costs represented 45.7% of
progressive disease management costs for both treatment
strategies, in line with the analysis from Singapore [21].
Post-discontinuation drug costs
Post-discontinuation drug costs (table 1) were estimated
based on unit costs from the SFOPH Spezialitätenliste and
KEYNOTE-024 resource use data on the distribution of
patients in the pembrolizumab and chemotherapy arms re-
ceiving second-line and third-line chemotherapy or im-
munotherapy (further details are provided in supplemen-
tary table S2, appendix 1), and the average number of days
patients received these treatments. As described above in
the section “Survival analysis”, a secondary analysis was
also undertaken where we assumed no second-line pem-
brolizumab was administered to chemotherapy patients, by
implementing an adjustment for treatment switching to the
model.
Terminal care costs
We only wished to include palliative care costs incurred
during the final 30 days of life as we assumed that care dur-
ing this time is typically provided in an inpatient setting in
Switzerland, and disease management in the earlier stages
of progressive disease is typically provided in an outpatient
setting (and the associated costs of this are separately ac-
counted for elsewhere in the model; see the section on
“Disease management costs”). However, we were not
aware of any studies in Switzerland that estimated the cost
of treating NSCLC patients during the last 30 days of life.
In order to derive this cost, we contacted a Swiss-based
lung cancer oncologist, who provided us with an estimate
of this cost of CHF 22,816 (table 1). This was the mean
cost based on a sample of 49 NSCLC patients who died in
a Swiss hospital in 2018.
Adverse event management costs
Costs related to hospitalisations for grade 3 to 5 adverse
events occurring in at least 5% of patients in either arm
were included in our analysis [8]. Pneumonitis was also in-
cluded on clinicians’ advice because although it was un-
common in KEYNOTE-024, it is nonetheless a well-docu-
mented adverse event for some patients on pembrolizumab
monotherapy [6]. Unit costs of adverse event hospitali-
sations were obtained from the Swiss DRG database sta-
tistics (table 1) [10]. Costs were estimated for each arm
by multiplying adverse event unit costs by the proportion
of occurrences for each adverse event for KEYNOTE-024
participants in each arm. This was further multiplied by the
percentage of each adverse event that was expected to re-
sult in hospitalisation, which was based on estimates pro-
vided by US clinical experts [8] and verified as transfer-
able to Switzerland by a Swiss oncologist we consulted.
Original article Swiss Med Wkly. 2019;149:w20170
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 13
Sensitivity analysis
Full details on the methods for the sensitivity analyses un-
dertaken are provided in supplementary table S3 (appen-
dix 1). As described in the previous sections, secondary
analyses were undertaken related to alternative choices of
the model time horizon and discount rate, assignment of
EQ-5D-3L scores to model states, adjustment of progres-
sion-free disease management costs based on an analysis
from Singapore, evaluation of a PD-L1 testing and treat-
ment strategy, alternative overall survival probability after
5 years, negating the effect of treatment switching, and re-
moving paclitaxel and carboplatin as a chemotherapy reg-
imen. One-way sensitivity analyses were done by imple-
menting plausible variations in key input parameters to
assess how this impacted the base-case ICER (full methods
are provided in table S3). This included plausible reduc-
tions to the parameters used for the extrapolations of over-
all survival and progression-free survival, which were key
areas of uncertainty in our analysis given the short dura-
tion of initial trial follow-up [7]. We did not vary the costs
of drugs as these are certain, and in a secondary analysis
used different assumptions for long-term overall survival
after 5 years (based on parametric extrapolations instead of
Swiss registry data) rather than varying this parameter in
a one-way sensitivity analysis. The results of the one-way
sensitivity analyses were presented in a Tornado diagram
(fig. 4). We also undertook probabilistic sensitivity analy-
sis (PSA) with 1000 iterations by assigning a probability
distribution to each key model input parameter (full details
are provided in table S3). For correlated parameters, a joint
distribution was assigned. If the standard error for the pa-
rameters was not empirically estimated (e.g., for all costs),
we assumed it was 20% of the mean parameter value. PSA
results were presented in a cost-effectiveness plane and ac-
ceptability curve.
Model validation
The previous US model which we adapted for Switzerland
satisfied the AdviSHE criteria for validating health eco-
nomic models [8]. All the changes we made to the US
model to reflect the Swiss situation (and the assumptions
underlying these changes) were validated by a Swiss on-
cologist, and a health economist who contributed to the US
model and several subsequent local adaptations.
The overall survival curve for the pembrolizumab strategy
predicted 25.2% of patients would survive 5 years after
treatment initiation (fig. 5), which is only slightly less
than the observed proportion from the KEYNOTE-001
trial of 29.6% of previously untreated advanced NSCLC
patients with PD-L1 expression ≥50% surviving 5 years
after treatment initiation with pembrolizumab [22]. This
suggests that the estimate of overall survival for patients
treated with first-line pembrolizumab in our model at 5
years is reasonably accurate. The overall survival curve for
chemotherapy patients following adjustment to negate for
treatment switching closely matched with the overall sur-
vival curve from Flatiron data of US metastatic NSCLC
patients initiating first-line cancer treatment measured over
approximately 3 years [8]. The projected 5 year survival
estimated by the model for chemotherapy patients follow-
ing adjustment to negate the effect of treatment switching
was 3.1%. The 5 year survival observed for Switzerland
estimated from NICER data of newly diagnosed stage 4
NSCLC patients between 2000 and 2016 was slightly high-
er (5.7%) [10].
Results
Base-case analysis
Over 20 years, pembrolizumab was projected to generate
mean incremental drug acquisition costs of CHF 69,909
(pembrolizumab CHF 88,985, chemotherapy CHF
19,076), mean incremental costs of the overall strategy of
CHF 77,060 (pembrolizumab CHF 223,324, chemothera-
py CHF 146,264), mean incremental QALYs of 1.34 (pem-
brolizumab 3.05, chemotherapy 1.71) and mean incremen-
tal life years of 1.69 (pembrolizumab 3.98, chemotherapy
2.28). The undiscounted gain in life expectancy was 2.07
years (pembrolizumab 4.61, chemotherapy 2.54). This led
to ICERs of CHF 57,402 per QALY gained and CHF
45,531 per life year gained (table 2). Thirty-one percent
Figure 3: Modelled progression-free survival.
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of patients in the pembrolizumab group and 0% in the
chemotherapy strategy were projected to still be on first-
line treatment at 2 years (fig. 2), with pembrolizumab pa-
tients still on treatment discontinuing at that time point.
Secondary analyses
Full results of the secondary analyses carried out for this
study are provided in table 3. Notably, the analysis of
an overall testing and treatment strategy (as opposed to
just treatment) led to an ICER of CHF 57,738 per QALY
gained. In the analysis where we assumed there was no
treatment switching for chemotherapy patients resulting in
lower costs and QALYs for the chemotherapy strategy,
higher mean incremental costs (CHF 126,416) and QALYs
(1.97) were projected relative to the base-case, leading to
an ICER of CHF 64,186 per QALY gained.
Using EQ-5D-3L scores assigned to each of the three dis-
ease states, as opposed to time-to-death EQ-5D-3L scores,
led to an ICER of CHF 59,519 per QALY gained. The
analysis where we applied probabilities of overall survival
based on parametric curves fitted after year 5 (instead of
using NICER data) led to an ICER of CHF 62,168 per
Figure 4: Tornado diagram for one-way sensitivity analyses.
Figure 5: Modelled overall survival (base-case).
Original article Swiss Med Wkly. 2019;149:w20170
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 7 of 13
QALY gained. Adoption of a 5-year time horizon resulted
in an ICER of CHF 87,071 per QALY gained.
Sensitivity analysis
We varied 26 parameters in one-way sensitivity analyses
and the 21 most influential parameters are presented in a
Tornado diagram (fig. 4). For 24 parameters, only small
changes to the base-case ICER resulted from varying them.
For two parameters, which related to overall survival with
the pembrolizumab and chemotherapy treatment strategies
respectively, there was a more substantial impact on cost
effectiveness. Noticeably, a pessimistic assumption that the
true value of the intercept of the exponential distribution
used to extrapolate overall survival with the pembrolizum-
ab treatment strategy is the lower bound of the 95% con-
fidence interval of its mean value resulted in a very high
ICER of CHF 306,585 per QALY gained. In the probabilis-
tic analysis, we estimated the probability of first-line pem-
brolizumab being cost effective is 88%, for a payer willing
to pay up to CHF 100,000 for an additional QALY (fig. 6).
Discussion
Based on the results of the KEYNOTE-024 trial, we found
that pembrolizumab is likely to be cost effective for treat-
ment in Switzerland. Relative to chemotherapy, the pem-
brolizumab treatment strategy was associated with higher
mean costs of CHF 77,060, gains in life years of 1.69 and
in QALYs of 1.34, leading to an ICER of CHF 57,402 per
QALY gained. By assuming either a Swiss threshold of
CHF 100,000 per QALY gained or a more conservative
threshold of one times the gross domestic product per capi-
ta of Switzerland (of CHF 79,104 per QALY or DALY in
2017) [23], we observed that the base-case ICER falls be-
low these values and in probabilistic sensitivity analyses,
pembrolizumab was 88% likely to be cost effective with
Table 2: Base-case results.
Pembrolizumab Chemotherapy Incremental pembrolizumab vs
chemotherapy
Life years 3.98 2.28 1.69
Progression-free state (months) 25.96 6.57 19.39
Progressive state (months) 21.74 20.83 0.92
QALYs 3.05 1.71 1.34
Total costs (CHF) 223,324 146,264 77,060
Drug acquisition 88,985 19,076 69,909
Pre-medication 0 170 −170
Drug administration 6806 3263 3543
Disease management 94,746 72,136 22,610
Post-discontinuation therapy 12,626 28,232 −15,605
Adverse events 514 2115 −1601
Terminal care 19,646 21274 −1627
ICER Cost (CHF) per life year 45,531
Cost (CHF) per QALY 57,402
ICER= incremental cost-effectiveness ratio; QALY= quality-adjusted life year
Table 3: Results of scenario analyses.
Description of scenario Pembrolizumab cost
(CHF)
Chemotherapy cost
(CHF)
Incremental
cost of pem-
brolizumab
(CHF)
Pembrolizumab
QALYs
Chemotherapy
QALYs
Incremental
QALYs of pem-
brolizumab
ICER (CHF/
QALY)
Base-case analysis 223,324 146,264 77,060 3.05 1.71 1.34 57,402
Test and treat strategy (includ-
ing PD-L1 test cost)
169,710 146,264 23,446 2.11 1.71 0.41 57,738
Discount rate: 0% for costs and
outcomes
243,829 156,180 87,649 3.54 1.91 1.64 53,591
Discount rate: 2% for costs and
outcomes
229,442 149,243 80,200 3.20 1.77 1.43 56,110
Discount rate: 6% for costs and
outcomes
208,231 138,831 69,399 2.69 1.56 1.13 61,362
Paclitaxel and carboplatin not
used in Switzerland
223,324 147,282 76,042 3.05 1.71 1.34 56,643
Parametric extrapolations for
OS after 5 years
198,814 133,110 65,703 2.45 1.39 1.06 62,168
Probabilistic results 225,363 151,838 73,525 3.06 1.77 1.29 56,887
EQ-5D scores assigned to pro-
gression-based states
223,324 146,264 77,060 2.90 1.60 1.29 59,519
Negate treatment switching in
chemotherapy arm
223,324 96,909 126,416 3.05 1.08 1.97 64,186
Progression-free disease costs
based on Singapore
225,244 142,692 82,552 3.05 1.71 1.34 61,493
Time horizon: 5 years 178,275 125,119 53,156 1.87 1.26 0.61 87,071
Time horizon: 10 years 201,300 136,634 64,666 2.51 1.50 1.01 64,083
Time horizon: 30 years 230,246 149,096 81,150 3.21 1.77 1.44 56,335
ICER = incremental cost-effectiveness ratio; OS = overall survival; PD-L1= programmed death ligand-1, QALY = quality-adjusted life year
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the CHF 100,000 per QALY threshold and 80% likely with
the CHF 79,104 threshold.
We performed a non-systematic literature search of cost-
effectiveness studies to confirm none have been performed
for this indication previously in Switzerland, and to assess
the comparability of our results for Switzerland with the
results for other countries (the non-systematic search may
mean we did not identify all relevant studies). Also based
on the KEYNOTE-024 trial, first-line pembrolizumab
monotherapy has previously been projected to be a cost-
effective treatment for metastatic NSCLC in patients with
TPS ≥50% in the USA [8, 24], Singapore [21], Hong Kong
[25] and France [26], but described as potentially not being
cost-effective in China [27] and the UK [24, 28] at its full
list price. A comprehensive review of the available analy-
ses is beyond the scope of the present paper, but important
variations in data and assumptions exist. Some authors re-
lied on the same modelling framework as used here, based
on access to primary data sources from the trial [8, 21, 25,
26]. Others applied purely literature-based modelling of ef-
fectiveness and costs [24, 27, 28]. The list price of pem-
brolizumab used in our analysis for Switzerland was quite
similar to the prices used in analyses for the UK and Chi-
na, whereas the cost-effectiveness thresholds used for eco-
nomic evaluations in the UK and China were lower than
in Switzerland [24, 27, 28]. Caution should be exercised in
evaluating and directly comparing.
Results are not generalisable to NSCLC patients with PD-
L1 TPS <50% or with baseline ECOG performance status
of 2 or higher. However, an area for future research may
be to investigate cost effectiveness of extending treatment
to patients with any PD-L1 expression, as pembrolizumab
was recently found to be clinically effective for patients
with TPS ≥1% in a separate trial and has consequently
received US Food and Drug Administration approval for
this indication [29]. Also, although this study only evalu-
Figure 6a: Cost-effectiveness plane for the probabilistic sensitivity analysis.
Figure 6b: Cost-effectiveness acceptability curve for the probabilistic sensitivity analysis.
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ated pembrolizumab monotherapy, pembrolizumab admin-
istered in combination with chemotherapy has been eval-
uated as an effective treatment in the KEYNOTE-189 and
KEYNOTE-407 trials [30, 31] and was subsequently ap-
proved in Switzerland as a treatment option for metastatic
NSCLC patients (and is awaiting approval for reimburse-
ment). A network meta-analysis by Kim et al. (which com-
bined the results of the KEYNOTE-189 and 407 trials
without accounting for the different treatment indications
used between trials in terms of types of chemotherapy
drugs administered and rules for discontinuing pem-
brolizumab) reported that combination therapy resulted in
a greater improvement in progression-free survival in the
PD-L1 ≥50% population than monotherapy [9]. However,
no trials have directly compared these treatments and there
remains considerable uncertainty about the relative effica-
cy of combination therapy compared with monotherapy [9,
32].
The cost of pembrolizumab (estimated at CHF 88,985 per
patient following discounting) was an important factor dri-
ving the higher incremental cost of the pembrolizumab
treatment strategy, as was the higher disease management
costs generated by patients in the pembrolizumab treat-
ment strategy as a result of them living longer than
chemotherapy patients. Secondary analyses evaluating the
overall TPS testing and treatment strategy, applying
EQ-5D-3L scores to progression-based disease states and
negating the impact on overall survival of chemotherapy
patients as a result of treatment switching to pembrolizum-
ab, resulted in small increases in the base-case ICER; as
did the majority of one-way sensitivity analyses. The ICER
increased to CHF 87,071 per QALY gained when using a
shorter model time horizon of 5 years, although a non-triv-
ial proportion of patients are projected to survive beyond
this time point, hence a 20 year time horizon was used
for the base-case analysis. An ICER substantially exceed-
ing CHF 100,000 per QALY gained resulted from a reduc-
tion in the intercept value of the exponential distribution
used to extrapolate overall survival for the pembrolizum-
ab treatment strategy, to the lower bound of its 95% CI.
However, we were able to validate our extrapolation of
KEYNOTE-024 overall survival with 5-year data from the
KEYNOTE-001 trial [22], which indicated that our extrap-
olation was a reasonably accurate estimate.
Not all patients discontinuing chemotherapy because of
disease progression are able to take a second-line therapy.
Some may die from disease complications while taking
first-line therapy, whereas others may be too frail at the
point of treatment discontinuation to take a second-line
treatment. Only 59% of KEYNOTE-024 chemotherapy
arm patients who discontinued first-line treatment received
a second-line therapy. Of chemotherapy patients who did
receive second-line therapy, 90% received second-line
pembrolizumab. Our analysis therefore suggests it may be
more clinically and cost-effective to offer pembrolizumab
as a first-line rather than second-line treatment within a se-
quence.
A strength of the analysis is the use of a partitioned sur-
vival model derived from primary access to the trial data.
The partitioned survival approach is commonly used for
evaluating the cost-effectiveness of cancer drugs [33]. Fur-
thermore, we used the approach recommended by the
NICE Decision Support Unit for fitting survival curves for
overall survival and progression-free survival, via a two-
phase piecewise approach utilising Kaplan-Meier proba-
bilities followed by a best-fitting parametric curve [15].
Our analysis was based on clinical effectiveness data from
a large randomised controlled trial, which is the only trial
that has been conducted specifically for the assessed popu-
lation.
A key limitation is the short median follow-up period of
trial participants of 11.2 months, generating uncertainty
when extrapolating costs and outcomes over 20 years.
One-way sensitivity analysis showed this uncertainty in
relation to overall survival could substantially impact the
ICER. Longer-term follow-up results from the
KEYNOTE-024 trial have recently become available, with
longer median follow-up of 25.2 months [6], which show
that the overall survival improvement from pembrolizum-
ab documented in the original analysis was maintained and
adverse event profiles were consistent with the original
analysis. This may suggest using the updated trial data
would be likely to produce a cost-effectiveness result simi-
lar to the one we found. Furthermore, we were able to val-
idate our estimates of overall survival at 5 years in both
treatment strategies using long-term external data, and use
Swiss external data to model overall survival after 5 years.
A further limitation was that the administration of pem-
brolizumab in the KEYNOTE-024 trial may slightly differ
to real-world practice, as KEYNOTE-024 participants in
the pembrolizumab arm were eligible to continue receiving
pembrolizumab after confirmed disease progression if ben-
efits were still being observed [7], although current treat-
ment guidelines in Switzerland prohibit this [5]. There-
fore, the costs and QALYs we estimated in our analysis
for the pembrolizumab treatment strategy may be slightly
higher than in real-world practice. Another potential lim-
itation was the use of international effectiveness and re-
source use results from the KEYNOTE-024 trial for our
analysis in Switzerland, although as a result of the advice
from a Swiss clinical expert that paclitaxel and carboplatin
is a very rarely used chemotherapy regimen in Switzerland,
we removed this regimen in a secondary analysis which
had small resulting impact on costs and cost-effectiveness.
To conclude, we found that pembrolizumab monotherapy
in lieu of chemotherapy is likely to be cost-effective for
first-line treatment of previously untreated metastatic non-
small cell lung cancer (NSCLC) with PD-L1 tumour pro-
portion score (TPS) ≥50% in Switzerland.
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Appendix 1 Supplementary tables
Table S1: Estimation of cost per dose of chemotherapy in base-case analysis.
First-line chemotherapy regimen Percentage of chemotherapy pa-
tients receiving regimen
Cost per 3-week treatment cycle
(CHF)
Pemetrexed + carboplatin 44% CHF 3832
Pemetrexed + cisplatin 24% CHF 3902
Paclitaxel + carboplatin 11% CHF 621
Gemcitabine + cisplatin 7% CHF 728
Gemcitabine + carboplatin 13% CHF 658
Weighted average cost of 3-week treatment cycle of chemotherapy (excluding pemetrexed maintenance) CHF 2834
Average cost per dose of pemetrexed maintenance* CHF 3693
* Pemetrexed maintenance was administered as a dose of 500 mg/m2 of body surface area, with a cost of approximately CHF 2018/m2, dependent on the size of the vial which is
purchased Mean baseline body surface area of European KEYNOTE-024 participants was 1.83m2We used the lowest priced drugs which are available in Switzerland to provide
a conservative estimation of the cost of chemotherapy in Switzerland
Table S2: Percentage of KEYNOTE-024 participants in each treatment arm receiving various therapies (or no therapy) following discontinuation of first-line therapy.
Pembrolizumab (%) Chemotherapy (%)
Did not receive second- and third-line therapy 56 41
Carboplatin + gemcitabine (second-line) 7 0
Carboplatin + paclitaxel + bevacizumab (second-line) 7 0
Carboplatin + pemetrexed (second-line) 20 0
Cisplatin + pemetrexed (second-line) 9 0
Docetaxel (second-line ) 0 1
Nivolumab (second-line) 0 4
Pembrolizumab (second-line) 0 53
Pemetrexed (second-line) 0 1
Second-line therapy followed by pemetrexed maintenance 11 0
Docetaxel (third-line) 3 9
Table S3: Specification of parameter variation for the sensitivity analyses.
Parameter One-way sensitivity analysis Probabilistic sensitivity analysis
Pembrolizumab overall survival: intercept of exponential dis-
tribution after 32 weeks.
Lower and upper bound of 95% CI of base-case value/s The variance of the parameter was used to gen-
erate random draws
Chemotherapy overall survival: intercept of exponential distri-
bution after 38 weeks.
Chemotherapy progression-free survival: intercept of expo-
nential distribution after 9 weeks.
Pembrolizumab progression-free survival: intercept and
ln(scale) of Weibull distribution after 9 weeks.
The covariance matrix of the parameter was
used to generate correlated random draws
Pembrolizumab time-on-treatment: mu, sigma and Q of gen-
eralised gamma distribution
Chemotherapy time-on-treatment: mu, sigma and Q of gener-
alised gamma distribution
EQ-5D-3L scores ± 20% of base-case value Beta distribution with mean and standard error
estimated from KN-024 data
Drug administration costs (first hour and subsequent hours) Lower and upper bound of 95% confidence interval of the
log-normal distribution of the base-case value
Log-normal distribution with standard error set at
20% of the mean cost
Disease management, post-discontinuation therapy and ter-
minal care costs
± 25% of base-case value Log-normal distribution with standard error set at
20% of the mean cost
Adverse event cost parameters ± 50% of base-case value Log-normal distribution with standard error set at
20% of the mean cost
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Table S4: Akaike information criterion and (Bayesian information criterion) estimates for each type of parametric curve for each outcome.
Model
Akaike information criterion Bayesian information criterion
Time-on-treatment models for pem-
brolizumab
Exponential 815.7 818.8
Weibull 778.8 784.9
LogNormal 783.6 789.7
LogLogistic 781.2 787.2
Gompertz 800 806.1
Generalised Gamma 780.4 789.5
Time-on-treatment models for chemother-
apy
Exponential 1127.9 1130.9
Weibull 1127.5 1133.6
LogNormal 1186 1192
LogLogistic 1169.3 1175.3
Gompertz 1128.7 1134.7
Generalised Gamma 1115.3 1124.3
Progression-free survival models for pem-
brolizumab, week 9+
Exponential 430.1 432.8
Weibull 424.1 429.6
LogNormal 427.3 432.8
LogLogistic 425.4 430.9
Gompertz 430.1 435.6
Generalised Gamma 425.3 433.5
Progression-free survival models for
chemotherapy, week 9+
Exponential 718 720.8
Weibull 719.4 724.9
LogNormal 749.2 754.7
LogLogistic 735.1 740.6
Gompertz 719 724.4
Generalised Gamma 714.4 722.6
Overall survival models for pembrolizumab Exponential 523.9 527
Weibull 525.6 531.7
LogNormal 525.1 531.1
LogLogistic 525 531
Gompertz 524.8 530.9
Generalised Gamma 526.8 535.9
32 weeks KM+exponential 115.8 118.5
Overall models for standard of care Exponential 696.2 699.2
Weibull 698.2 704.3
LogNormal 694 700.1
LogLogistic 696.3 702.3
Gompertz 697.4 703.5
Generalised Gamma 695.6 704.7
38 weeks KM+exponential 94.6 96.8
Bold rows represent the models which were eventually selected for the base-case analysis
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